Fri, Mar 6, 2015, 5:41 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

slcimmuno 11 posts  |  Last Activity: Feb 26, 2015 3:25 PM Member since: Jun 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    a new Cellceutix recap article worth a read

    by slcimmuno Feb 26, 2015 2:19 PM
    slcimmuno slcimmuno Feb 26, 2015 3:25 PM Flag

    yeah nothing new but a solid recap, useful for newbites to the stock - i have a sm stake in Gale and, yeah, know that fiasco quite well... i dont think cellceutix is working w them --- lets hope not. still lots to look fwd to with CTIX and its promising phenom pipeline

  • it's under the title
    Cellceutix Corp. is "One to Watch" -- search for this (a good recap of the company/pipeline)

  • thats at least how i view CTIX's pipeline....
    im thinking we're going to bat at least 2 for 3
    just give it some time

  • Reply to

    questions

    by sockwellsam Feb 9, 2015 3:42 PM
    slcimmuno slcimmuno Feb 9, 2015 4:40 PM Flag

    id recommend surfing on over to IHUB as part of your due diligence ... lots of informed folks who have been Long CTIX for quite a while.

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 30, 2015 5:19 PM Flag

    some data quantifying $ impact of bad bugs: the Alliance for the Prudent Use of Antibiotics (www.APUA.org) at Tufts University said ***the cost in 2009 to treat one patient with an antibiotic-resistant infection was $18,588 to $29,069.*** The economic burden on the health care system from resistant infections was $20 billion annually. One such infection in a hospitalized patient ***adds 6.4 to 12.7 days to that patient’s stay,*** APUA said. These infections also cause a ***200% increase in the risk of death for hospitalized patients, APUA said. brilacidin, even if priced high, will be justified given the significant LOS cost savings.

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 30, 2015 9:58 AM Flag

    its a legit email. im not going to post his email address. take it for what it's worth. brilacidin is based on lots of earlier hi-q research done by Polymedix--NIH grants, biomemetic computer modeling by U Penn researchers (DeGrado...google the Forbes story on him)... there are others trying to play catchup... defensin-mimetic research out of U of MD and Ohio State that further reinforce the MOA (lysis). CTIX via its acquisition of the Polymedix IP portfolio is just years ahead of everyone else. Brilacidin is just the first drug of many to come... anti-fungals, gram-negative, malarial, TB... then there are industrial-material applications of the science (google PolyCide).

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 30, 2015 9:52 AM Flag

    thx rayonman--i spend most of my time on another board but find your commentary insightful, fair and balanced... i believe we have a winner w Brilacidin---so much pressure to get new antibiotics to market. to wit, bothABSSSI drugs approved in 2014, with unanimous recommendations by the Anti-Inf Adv Cmte. its the strong Ph II results that should hold i think as we move into Ph III. also failure rates of initial drugs for ABSSSI are 26%. with Brilacdin's MOA this likely won't be the case... and yes, whether its 5 or 7 days shaved off LOS there is money to be saved.

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 29, 2015 1:34 PM Flag

    PART THREE ] Bottom line for profits - ABX are big profit medications.... when people need them, insurnace and hospitals will pay. There haven't been new class of meds in 30 years, so this should hit the market nicely. The 1/2 life and potency makes dosing easy and will make prescribers quick to adopt. And the low liklihood of resistence makes it have staying power. So Id say you have a lot of the makings of not only a very good drug, but a profitable one. The big caveat is the PhIII trials. In fact, when you look at it, Brilicidin and Teixobactin may just be the best 1-2 punch you can think of. they both attack the cell walls, one works better for G-, the other for G+, both have long 1/2 life, one bacteriCIDAL the other bacterioSTATIC.

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 29, 2015 1:34 PM Flag

    PART TWO By then, if you had chosen the wrong med, then you are behind the eight ball. We also need new antibiotics that can tackle these muti drug resistant strains that are devastating our hospitals. I love the long half life and long activity level, combined with the high potency. 1x dose killed 92% 3 days dosing was 98% in the study you shared. Thats fantastic (7 days of dapto was 94%). The reason docs prescribe azithromycin over most any other respiratory medication is because its 5 days of treatment with a half life that lasts for 10-14 days... so you have better patient compliance and easier Rx to write. This, i'm sure will follow that same path... but the kicker is the 1x dosing - which could be done in the ER and no Rx needed to send the pt home. (we do this for strep throat with 1.2 million units of Penicillin G or K - and also one time dose to treat 2 of the STD's out there, but thats about the only 1x shot that we can do - and we love it because we have 100% compliance and know the patient is getting the appropriate treatment, regardless of their insurance status or ability to pay for the Rx or compliance with taking it. You have to be careful when you start to believe things like "smaller side effect profile" because with a new drug, you have no idea. They are not testing in high enough populations to find out. Phase III trials may also not tell you the whole picture, often we get the bigger picture when the come to market - and then it can kill the drug if there is a rare but severe side effect that simply hadn't shown up in the prior trials due to smaller sample size. The gram neg application is my favorite - it is so broad. It is bound to be a big winner.

  • Reply to

    QIDP update

    by drionache Jan 29, 2015 10:17 AM
    slcimmuno slcimmuno Jan 29, 2015 1:31 PM Flag

    ED Doc friend's take on Brilacidin. PART ONE EMAIL This is really cool, I hadn't heard of this before For starters, there hasn't really been a new class of antibiotics since 1987 when the lipopeptides were first on the market. Since then we have had things like tigicillin and linezolid and other suped-up high potency last-line antibiotics that we reserve for multi-drug resistant or critically ill patients, but truly there has been no new class to market for about 30 years! When I first started to read your email I was thinking about teixobactin. It is toxic to bacteria but not mamalian tissue due to its affect on essential fatty acids specific to (gram positive) bacterial cell walls (something so ubiquitous that it doesn't seem likely resistance could easily be developed in time) - but has no effect on mammalian tissue. Thus it works great on MRSA and mycobacterium Tuberculosis and others (but not gram negatives). It is indeed bacterioSTATIC but not bacterioCIDAL, because it inhibits cell wall synthesis (by binding to the highly conserved motif on Lipid II and Lipid III - precursors to Peptidoglycan and Teicholic Acid) , impairing their ability to reproduce. It seems incredibly promising. Nature article (takes a whilet to load): http://www.nature.com/articles/nature14098.epdf Looking specifically at this Brilicidin, I think it has incredible potential as well. The fact that it covers G+ and G- allows it to be broad spectrum, which clinically is incredibly important, as we don't always know what bug we are treating until 2-3days into treatment when the cultures begin to grow out.

  • slcimmuno by slcimmuno Dec 12, 2014 1:42 PM Flag

    http://blogs.fda.gov/fdavoice/index.php/2014/12/2014-drug-approvals-speeding-novel-drugs-to-the-patients-who-need-them/
    And this
    http://www.raps.org/Regulatory-Focus/News/2014/12/11/20966/Bill-Seeks-Creation-of-New-Pathway-for-Antibiotic-Drug-Approvals/

    Definitely good timing

    Sentiment: Strong Buy

IMUC
0.5934-0.0036(-0.60%)Mar 6 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.